Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.

Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, Dalvie D.

Drug Metab Dispos. 2011 Mar;39(3):539-50. doi: 10.1124/dmd.110.037101. Epub 2010 Dec 14.

2.

Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

Gay SC, Roberts AG, Maekawa K, Talakad JC, Hong WX, Zhang Q, Stout CD, Halpert JR.

Biochemistry. 2010 Oct 12;49(40):8709-20. doi: 10.1021/bi100914z. Epub 2010 Sep 15.

3.

Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.

Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, Zhang Q, Stout CD, Halpert JR.

Mol Pharmacol. 2010 Apr;77(4):529-38. doi: 10.1124/mol.109.062570. Epub 2010 Jan 8.

4.

Rational engineering of cytochromes P450 2B6 and 2B11 for enhanced stability: Insights into structural importance of residue 334.

Talakad JC, Wilderman PR, Davydov DR, Kumar S, Halpert JR.

Arch Biochem Biophys. 2010 Feb 15;494(2):151-8. doi: 10.1016/j.abb.2009.11.026. Epub 2009 Nov 26.

5.

Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.

Talakad JC, Kumar S, Halpert JR.

Drug Metab Dispos. 2009 Mar;37(3):644-50. doi: 10.1124/dmd.108.023655. Epub 2008 Dec 12.

Supplemental Content

Loading ...
Support Center